The world apheresis association registry, 2023 updateDepartment of Clinical Immunology and Transfusion Medicine, and Department of Biochemical and Clinical Sciences, Linköping University, Linköping, Sweden.
Department Haematology, University Hospital, Ankara, Turkey.
Department Haematology, University Hospital, Ankara, Turkey.
Nephrocare Rostock GmbH, Rostock, Germany.
Dep of Immunology and Transfusion Medicine, Akershus University Hospital, Lorenskog, Norway.
AZ Delta, Roeselare, Belgium.
Clinical Department of Transfusion Medicine and Transplantation Biology, University Hospital Centre Zagreb, Croatia.
IV. Internal Hematological Klinik, Fakultni Nemocnice, Hradec Králové, Czech Republic.
IV. Internal Hematological Klinik, Fakultni Nemocnice, Hradec Králové, Czech Republic.
Apheresis Department, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
Apheresis Department, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
Blood Centre, University Hospital Ostrava, Ostrava, Czech Republic.
Blood Centre, University Hospital Ostrava, Ostrava, Czech Republic.
Therapeutic apheresis unit, Vilnius university hospital Santariskiu clinics, Vilnius, Lithuania.
Therapeutic apheresis unit, Vilnius university hospital Santariskiu clinics, Vilnius, Lithuania.
South African National Blood Service, Johannesburg, South Africa.
Apheresis Center, University Hospital, Örebro, Sweden.
Department of Nephrology, University Hospital, Uppsala, Sweden.
Bone Marrow Transplant & Apheresis, Apheresis & Cell Therapies Unit, Concord Repatriation General Hospital, NSW, Concord, Australia.
The Institute for the Diagnosis and Therapy of Atherosclerosis and Fat Metabolism Disorders, Athos, Vienna, Austria.
St. Anna Kinderspital, University Hospital, Vienna, Austria.
Show others and affiliations
2023 (English)In: Transfusion and apheresis science, ISSN 1473-0502, E-ISSN 1878-1683, Vol. 62, no 6, article id 103831Article, review/survey (Refereed) Published
Abstract [en]
The WAA apheresis registry contains data on more than 140,000 apheresis procedures conducted in 12 different countries. The aim is to give an update of indications, type and number of procedures and adverse events (AEs).
Material and Methods: The WAA-registry is used for registration of apheresis procedures and is free of charge. The responsible person for a center can apply at the site www.waa-registry.org
Results: Data includes reported AEs from 2012 and various procedures and diagnoses during the years 2018–2022; the latter in total from 27 centers registered a total of 9500 patients (41% women) that began therapeutic apheresis (TA) during the period. A total of 58,355 apheresis procedures were performed. The mean age was 50 years (range 0–94). The most common apheresis procedure was stem cell collection for which multiple myeloma was the most frequent diagnosis (51%). Donor cell collection was done in 14% and plasma exchange (PEX) in 28% of patients; In relation to all performed procedures PEX, using a centrifuge (35%) and LDL-apheresis (20%) were the most common. The main indication for PEX was TTP (17%). Peripheral veins were used in 56% as the vascular access. The preferred anticoagulant was ACD. AEs occurred in 2.7% of all procedures and were mostly mild (1%) and moderate 1.5% (needed supportive medication) and, only rarely, severe (0.15%).
Conclusion: The data showed a wide range of indications and variability in apheresis procedures with low AE frequency.
Place, publisher, year, edition, pages
Elsevier, 2023. Vol. 62, no 6, article id 103831
Keywords [en]
Adverse events, Apheresis, Indications, Procedures, Register
National Category
Hematology
Identifiers
URN: urn:nbn:se:umu:diva-215382DOI: 10.1016/j.transci.2023.103831ISI: 001132281600001PubMedID: 37827962Scopus ID: 2-s2.0-85173651523OAI: oai:DiVA.org:umu-215382DiVA, id: diva2:1808074
2023-10-302023-10-302025-04-24Bibliographically approved